Business development agreement provides expanded reach of FDA-cleared automated imaging software to improve physician efficiency and accuracy
(SAN DIEGO, CA) July 24, 2020 – Cortechs.ai and Subtle Medical join together to increase global access to medical imaging solutions. The non-exclusive business development agreement expands Subtle Medical’s automated image reconstruction solutions to Cortechs.ai’ global customer base via its internal sales and marketing teams.
Subtle Medical’s software solutions, SubtleMR™ and SubtlePET™, are the first FDA-cleared AI-powered software applications approved for medical imaging enhancement. SubtleMR applies two methods of image enhancement—denoising and increasing image sharpness—to improve image quality, while SubtlePET denoises scans that were conducted in 25% of the original scan duration. Both software solutions allow centers to provide a better patient experience and increase throughput by maintaining the superior image quality of a site’s accelerated scan protocols.
Subtle’s solutions complement the Cortechs.ai quantitative volumetric analysis software portfolio and can be combined to increase radiology efficiency while enhancing clinical findings and analysis. The software integrates seamlessly with any PET or MRI scanner and PACS to enhance images during acquisition without any alteration to existing workflows.
Cortechs.ai’ flagship product, NeuroQuant®, uses machine learning to provide automatic segmentation overlays and quantification of brain structures and lesions from MRI, revealing the presence of various biomarkers. Values are compared to a unique normative database of patients of the same age and sex to aid physicians in making clinical decisions regarding neurodegenerative diseases.
PETQuant™ is a research-specific component of NeuroQuant that provides physicians with a cutting-edge analysis tool in the study of dementia and Alzheimer’s disease. It allows for automated and fast analysis of PET brain studies by segmenting brain structures and quantifying subregional tracer binding in native patient brain space.
In a recent abstract submission to the American Society of Neuroradiology’s annual meeting titled, “Deep Learning Enables Accurate Quantitative Volumetric Brain MRI with 2x Faster Scan Times”, co-authored by Dr. Suzie Bash, a prominent neuroradiologist with RadNet, the largest US outpatient radiology network, the companies found that the NeuroQuant segmentation and volumetric outputs between the SubtleMR acquired series and the standard scan series were quantitatively similar, indicating that SubtleMR can enable accurate segmentation and volumetric measurements using NeuroQuant in half the amount of time. In a period when imaging facilities are slowed due to COVID-19 sanitation procedures, the time gained via SubtleMR is a major workflow improvement. Facilities can reduce scan time without sacrificing critical volumetric analysis that may otherwise not allow for shorter imaging sequences.
“RadNet’s recent research demonstrated that deep learning reconstruction of brain MR imaging with SubtleMR effectuates enhanced image quality, as well as greater efficiency with significant scan time reduction,” said Dr. Suzie Bash, Neuroradiologist, RadNet. “It also maintained high volumetric quantification accuracy with NeuroQuant, which suggests promise for reliability, consistency, and utility of both applications in routine clinical practice.”
“By joining forces with Cortechs.ai, we can work together to provide increased clinical value to radiologists and neurologists while improving the radiology workflow and patient experience at the same time,” said Enhao Gong, Founder and CEO of Subtle Medical. “We are excited about taking this step to transform care delivery.”
“I am very excited to partner with Subtle Medical to expand the clinical utility of our radiology imaging solutions in the worldwide market,” said Dr. Chris Airriess, CEO of Cortechs.ai. “The reduced acquisition time of Subtle’s scans that perform equivalently, from a quantitative perspective, to native acquisitions will greatly benefit the workflow efficiency of our clinical partners and allow advanced volumetric imaging solutions to be deployed more widely across our customer base, leading ultimately to better patient care.”
About Cortechs.ai, Inc.
Cortechs.ai is the leader in radiology AI applications, using cutting-edge advances in medical imaging to revolutionize disease screening and early detection so people can enjoy longer, better lives. The company develops and markets breakthrough medical device software solutions that quantify and track neurodegenerative and cancerous conditions. Cortechs.ai’ cutting-edge brain imaging analysis provides neurologists, radiologists, oncologists, and clinical researchers worldwide with a convenient and cost-effective means to quantify brain structures to help assess a variety of neurological conditions, such as Alzheimer’s disease, epilepsy, multiple sclerosis, brain trauma, and brain development abnormalities. The company has FDA-cleared products for use in the diagnosis of neurodegenerative and traumatic brain conditions as well as prostate cancer. Please visit cortechs.ai for further information and follow us on Twitter, LinkedIn, and Facebook.
About Subtle Medical
Subtle Medical, Inc. is a healthcare technology company with a suite of deep learning solutions that improve workflow efficiency and patient experience. The company has the first AI software solutions FDA-cleared for medical imaging enhancement, SubtlePET™ and SubtleMR™. It was named in the CB Insights Top AI 100 in 2020. Current clinical partners include UCSF, Hoag Hospital, UCSD, Toronto Sickkids, Radnet, DASA, Tiantan Hospital, and Middlesex Hospital, among others. Subtle Medical is based out of Menlo Park, CA. For more information, please visit subtlemedical.com or email sales@subtlemedical.com.
Contacts:
Travis Foegler
Cortechs.ai
Phone: +1 (619) 450-9094
Email: tfoegler@cortechs.ai
Anna Menyhart-Borroni
Subtle Medical
Phone: +1 (501) 766-2662
Email: anna@subtlemedical.com
###
